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Role of elosulfase alfa in mucopolysaccharidosis 
IVA
Debra S Regier 
Pranoot Tanpaiboon
Division of Genetics and Metabolism, 
Children’s National Medical Center, 
Washington, DC, USA
Abstract: Mucopolysaccharidosis type IVA (MPS IVA or Morquio A) is an autosomal recessive 
lysosomal storage disease which results in a striking skeletal phenotype, but does not negatively 
impact the intellect of the patient. MPS IVA has a phenotypic continuum that ranges from a 
severe and rapidly progressing form to a slowly progressive form. The clinical diagnosis is often 
made in the preschool years based on abnormal bone findings on physical examination and 
dysplasia on radiographic imaging. Supportive care has been the mainstay in caring for patients. 
Orthopedic physicians often form the core of the care team due to the early and severe skeletal 
abnormalities; however, systemic disease is common and requires aggressive monitoring and 
management. Interdisciplinary care teams often consist of medical geneticists, cardiologists, 
pulmonary specialists, gastroenterologists, otolaryngologists, audiologists, and ophthalmolo-
gists. With the US Food and Drug Administration’s approval of elosulfase alfa, patients >5 years 
of age now have access to this medication from the time of diagnosis. The clinical trial with 
once weekly intravenous dosing (2.0 mg/kg per week) showed improvement in the 6-minute 
walk test. The composite end point analysis to evaluate the combining changes from baseline 
in 6-minute walk test, 3-minute stair climb test, and respiratory function showed that at a dose 
of 2.0 mg/kg per week, subjects performed better when compared to placebo. This indication 
was clinically meaningful in the treatment group. The treatment was generally well tolerated, 
and the uncommon infusion reactions responded well to traditional enzyme replacement therapy 
infusion reaction management algorithms. Currently, clinical trials are underway to determine 
the efficacy and safety in MPS IVA patients <5 years of age. 
Keywords: mucopolysaccharidosis type IVA, elosulfase alfa, enzyme replacement therapy, 
Morquio syndrome, lysosomal storage disease, keratan sulfate
Introduction
Lysosomal storage disorders (LSDs) are a group of over 50 inherited disorders that 
affect the function of lysosomes. These organelles are responsible for metabolizing 
and recycling several macromolecule cellular components. Thus, dysfunction of these 
organelles leads to lysosome damage and often abnormalities of the lysosome anatomy. 
LSDs are classified based on the major accumulated substrate, underlying mechanism, 
or defective enzyme. Subgroups of each disorder are usually further subdivided based 
on their age of symptom onset (reviewed in Hendriksz et al1 and Regier et al2).
The mucopolysaccharidoses are a group of LSDs characterized by the accumula-
tion of glycosaminoglycans, namely mucopolysaccharides. Mucopolysaccharidoses 
are classified into seven types (type I, II, III, IV, VI, VII, and IX) based on the accu-
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mulation of storage products and the underlying enzymatic 
deficiency. Mucopolysaccharidosis type IVA (MPS IVA) is 
an autosomal recessive LSD caused by genetic changes in 
the gene GALNS, leading to deficient or ineffective activity 
of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase 
(GALNS). This rare disease has an incidence of 1 in 71,000 
to 1,179,000.3 GALNS hydrolyzes the sulfate located on the 
ends of keratan sulfate (KS) and chondroitin-6-sulfate (C6S). 
Therefore, deficiency of GALNS leads to accumulation of 
KS and C6S.
MPS IVA caused by GALNS is clinically identical to 
MPS IVB, which causes the deficiency of β-galacotosidase 
(reviewed in Regier and Tifft4). Thus, it is important that 
enzymatic and/or genetic testing be performed to determine 
the underlying enzymatic defect in MPS IV since enzyme 
replacement is available in MPS IVA but not in MPS IVB.
The natural history of MPS IVA
MPS IVA was originally described  by orthopedic experts due 
to the severity of the skeletal dysplasia; however, as skeletal 
management has improved, the natural history of this disor-
der has expanded to include respiratory, heart, hearing, eye, 
dental, and liver involvement. Thus, patients with MPS IV 
are followed by multidisciplinary teams to optimize their out-
comes, often with orthopedics at the center of the care group.2
At birth, children with MPS IV have no unique identifiers. 
However, within the first few years of life, the most severe 
patients present with physical examination findings consistent 
with bony abnormalities. Kyphoscoliosis, genu valgum, and 
pectus carinatum are the most common presenting symp-
toms.5 The milder forms of MPS IV often present with hip 
problems such as pain, stiffness, and Legg-Calve-Perthes 
disease in late childhood or adolescence. In both cases, pro-
gressive bone and join involvement over time leads to short 
stature, pain, and arthritis. The bone progression can become 
disfiguring and lead to pain as well as impaired mobility and 
ability to perform activities of daily living (ADLs). Often, 
patients notice difficulty with hand strength and dexterity due 
to bony changes in the hands and lower arms. The more dev-
astating skeletal concern, odontoid hypoplasia with cervical 
instability can lead to neurological damage and devastating 
neurological outcomes.5 Spinal canal stenosis could occur at 
any level. Upper and lower extremities malalignment are uni-
versal, but the severity varies. Common skeletal abnormali-
ties include ulnar deviation of the wrist joint, hip dysplasia, 
hip dislocation, and genu valgum. Growth abnormalities 
are universal findings and usually severe. Height velocity is 
normal until 1–2 years old and then falls below normal.1,6
Extraskeletal manifestations of MPS IVA are similar to 
other MPS and include impaired respiratory function, val-
vular heart disease, obstructive sleep apnea (OSA), hearing 
impairment, corneal clouding, dental abnormalities in both 
shape and structure, and, less commonly, hepatomegaly.2
The longitudinal, prospective Morquio A clinical assess-
ment program reviewed a decline of endurance tests, 6-minute 
walk test (6MWT), and 3-minute stair climb test (3MSCT), 
suggesting decreased functional ability over time.7 Both 
endurance tests have been used to monitor overall disease 
progression in the clinic and in elosulfase alfa clinical tri-
als. The 6MWT assesses the walking distance in 6 minutes, 
and the 3MSCT assesses the number of stairs that subjects 
can climb within 3 minutes. These functional endurance 
tests are used as an indirect assessment of determining the 
overall function and integrated responses of multiple systems 
working together, including musculoskeletal, neurological, 
cardiovascular, and pulmonary systems.
Besides the progression of bone pathology and decline 
of endurance, natural history studies have revealed that other 
organ systems also show progressive symptoms. Significant 
morbidity is observed due to nonskeletal involvement.8 In 
a natural history study over 2 years, changes in the forced 
vital capacity (FVC) and maximum voluntary ventilation 
(MVV) were observed. For patients <14 years, the values 
increased, as would be expected for growth; however, the 
values decreased in older patients, which raised concerns 
about disease progression.7 The compromised respiratory 
function and decreased FVC and MVV are related to mul-
tiple factors, including progression of bone abnormalities 
and airway obstruction.
MPS IVA is a progressive condition and affects multiple 
organ systems. Life expectancy is shortened in the severe 
form, and general well-being is impaired. Bone abnormali-
ties leading to joint and bone deformities and spinal cord 
compression are the major cause of mobility limitation, pain, 
and difficulties in ADLs. Several factors affect respiratory 
function such as short stature, chest wall abnormalities (pec-
tus and kyphoscoliosis), and chronic OSA.
Current management strategies for 
symptoms of MPS IVA
A multidisciplinary approach is the key to management. 
Careful management with orthopedic intervention when 
necessary is crucial for MPS IV patients.2 In cases of dif-
ficult airway secondary to glycosaminoglycans accumula-
tion in both upper and lower airway, odontoid hypoplasia, 
impaired respiratory function, and cardiac problems, it is 
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Table 1 Monitoring recommendations for mucopolysaccharidosis type IVA (MPS IV) patients
At diagnosis Every 6 mo Annually Every 1–3 yr
Medical history Medical history Eye examination Electrocardiogram
Physical examination Physical examination Hearing test Echocardiogram
Growth evaluation Growth evaluation Pulmonary function Spine MRI
Neurological examination Neurological examination Electrocardiogram Sleep study
Eye examination Dental evaluation Echocardiogram
Hearing test Endurance test
Pulmonary function Quality of life and pain assessment










Note: Data from Regier et al.2 aMultiple evaluations performed at the time of diagnosis for baseline measurements should be repeated, as clinically indicated.
Abbreviation: mo, months; yr, years; ADL, activities of daily living.
crucial that anesthesia care be administered by teams that 
understand the needs of the MPS IV population.9 Due to the 
severe growth abnormalities, specific growth charts have 
been developed to allow for normalization of children’s 
growth.10 Abnormalities of the spine and malalignment 
of both upper and lower extremities are progressive and 
could lead to disability. Patients should be evaluated by 
orthopedics and neurosurgery closely, at least annually. 
Neurological examination should be performed at least 
every 6 months due to the risk of spinal cord compression. 
This would likely include radiography of spine and lower 
extremities, as well as whole-spine MRI annually and when 
clinically indicated.
Pulmonary specialty involvement is essential to manage 
respiratory compromise and sleep apnea.2 Close follow-up by 
a cardiology team is needed to monitor for and treat valvular 
heart disease.6 An audiology team follows and treats hearing 
impairment aggressively. Eye examinations and intervention 
for corneal clouding is important to optimize visual outcomes 
in patients.8 While the hepatomegaly noted in patients is not 
acutely dangerous, the liver size can affect other organs due 
to the short stature of patients. Finally, dental abnormalities 
can lead to pain and cosmetic difficulties if appropriate dental 
care is not identified early.8 Use of multidisciplinary clinics 
often improves patient satisfaction and quality of life by 
reducing the total number of hospital visits and facilitation 
of care coordination.
Within the context of the numerous systemic compli-
cations, it is crucial that the care delivery team optimize 
learning and social environments for families with MPS IV. 
Baseline intelligence is normal; thus, optimization of the 
environment and neurologic protection to prevent damage 
is crucial for outcomes.2 
In 2014, the “International guidelines for the management 
and treatment of MPS IVA syndrome” was released.1 These 
guidelines were a summary of two meetings of international 
experts with extensive experience in managing MPS IVA. 
As summarized in Table 1, the recommendations include an 
extensive baseline evaluation, with reevaluation at intervals 
to identify systemic changes early to allow for monitoring 
and intervention.
Treatments for MPS IV have been limited to support-
ive care until recently. For example, adenotonsillectomy 
for OSA, hearing aids for sensorineural hearing loss, and 
keratoplasty for corneal clouding have been recommended. 
Aggressive supportive and symptomatic surgical and non-
surgical interventions for skeletal abnormalities have been 
used. While other MPS were shown to have benefited from 
hematopoietic stem cell transplantation, the experience 
with MPS IV has been limited and benefits have not been 
well defined.2
Pharmacology, mode of action, 
pharmacokinetics of elosulfase alfa
Enzyme replacement therapy (ERT) has become a standard 
of care for many forms of LSDs. The first ERT was approved 
for Gaucher disease in 1996. The limitations of ERT are infu-
sion reaction, high cost, and low penetration of the central 
nervous system. With more clinical experience, the algorithm 
to prevent and manage infusion reactions has improved. The 
cost continues to be a major hurdle for treatment and an 
important conversation in the treatment of rare diseases. The 





low penetration of enzymes through the blood–brain barrier, 
leading to low central nervous system penetration, limits the 
efficacy of all ERTs. For example, ERT for Gaucher disease 
shows improvements in systemic symptoms of type I patients; 
however, the most severe forms – type II and III – with neuro-
logical regression and early death do not show improvement 
with peripheral administration of ERT. Thus, the efficacy of 
ERT in these cases is limited and does not change the end 
outcome – death from neurological complications. Since 
MPS IVA does not have effects on the intellect of patients, 
it makes it a perfect candidate for ERT, providing beneficial 
outcomes. It is important to note that the enzyme treatment 
can prevent disease progression to a certain extent but cannot 
reverse most of the pathology present from before treatment. 
Currently ERT has been approved for four types of MPS: 
MPS I (laronidase; Aldurazyme®, Genzyme, Boston, MA, 
USA), II (idursulfase; Elaprase®, Shire, Dublin, Republic of 
Ireland), IVA (elosulfase alfa; Vimizim®, Biomarin, Novato, 
CA, USA), and VI (galsulfase; Naglazyme®, Biomarin).
Elosulfase alfa mechanism of action
ERT is available only as an intravenous infusion formulation. 
The mechanism of action is to provide the enzymatic activity 
deficient due to MPS IVA.
Elosulfase alfa is a purified human enzyme produced 
using recombinant DNA technology (recombinant human 
enzyme or rhGALNS) in the Chinese hamster ovary cell 
line. The sequence and enzymatic activity of elosulfase alfa 
is identical to the human form. Elosulfase alfa is identical 
to the natural human enzyme in terms of the amino acid 
sequence and N-linked glycosylation.11,12 One of the oligo-
saccharide chains contains bis-mannose 6 phosphate, which 
binds a receptor at the cell surface (cation-independent 
mannose-6-phosphate receptor). Elosulfase alfa replaces 
the endogenous enzyme GALN and leads to catabolism of 
glycosaminoglycans C6S and KS.13,14 The enzyme is active in 
low pH environments and therefore has low activity outside 
of lysosomes.
Pharmacokinetics and pharmacodynamics
In humans, pharmacokinetics (PKs) and pharmacodynamics 
of elsosulfase alfa were studied in Phase I/II (MOR-002), 
Phase II (MOR-008), and Phase III (MOR-004) clinical tri-
als. MOR-002 is a completed Phase I/II, multicenter, open-
label, dose escalation study. The primary objectives were 
to evaluate the safety, tolerability, and efficacy of weekly 
infusion of elosulfase alfa (BMN110). The study enrolled 20 
subjects aged 5–18 years with MPS IVA. Subjects received 
elosulfase alfa over a 36-week dose escalation period of 12 
weeks each of 0.1, 1.0, and 2.0 mg/kg per week, followed 
by 36–48 weeks of additional treatment at 1.0 mg/kg per 
week. MOR-004 is a multinational, multicenter, double-blind, 
randomized, placebo-controlled, 24-week Phase III study in 
patients with Morquio A syndrome. The objective of this 
study was to determine two different dose regimens (2.0 
mg/kg per week and 2.0 mg/kg every other week [QOW]) 
infused intravenously compared to placebo for a total of 
24 weeks. MOR-008 is the ongoing Phase II, randomized, 
double-blind, multicenter, pilot study of BMN110 dose 2.0 
and 4.0 mg/kg per week administered for an initial treatment 
period of 27 weeks.
MOR-002 revealed that the PK profile of elosulfase alfa 
is not linear over the dose range of 0.1–2.0 mg/kg per week. 
The mean values for area under the plasma concentration time 
curve from time zero to the time of last measurable concen-
tration (AUC
0–t
) and maximum plasma concentration (C
max
) 
increased more than the increase in dose.11 In vitro studies 
in human fibroblasts when using 2.0 mg/kg per week yielded 
plasma concentration higher than those seen with 1.0 mg/kg 
QOW; C
max
 2,023 and 503 ng/mL, respectively. Furthermore, 
the plasma concentration of elosulfase alfa at 2.0 mg/kg per 
week was sustained above the K
uptake
 (2.8–4 nM) of the M6PR 
for approximately 6 hours, which was around 1 hour longer 
than those seen in dose 1.0 mg/kg QOW.11
According to data from MOR-004 for both dosing 
regimens – 2.0 mg/kg per week and 2.0 mg/kg QOW – elo-
sulfase alfa was detected in plasma at the first time point 
60 minutes after starting infusion and reached maximum 
concentration between 120 and 240 minutes.15,16 Plasma 
half-life was short in both dosing regimens; at week 0, t
1/2
 
was 7 minutes for both groups; and at week 22, t
1/2
 was 
19 and 36 minutes in QOW and weekly dosing groups, 
respectively.11,19 On the other hand, the in vitro study in 
human Morquio fibroblast showed a half-life of 5–7 days.11 
The results indicated that the enzyme’s half-life in plasma 
is shorter than in tissue, consistent with the uptake of the 
enzyme from the plasma to the tissue, as seen in other ERT 
regimens previously described.
The safety of a high dose (4.0 mg/kg per week) was 
studied in Phase II MOR-008. The results were similar to 
MOR-004 in that after week 22, the mean t
1/2
 was less than 
an hour, although with high dose at week 23, the mean t
1/2s
 
were 23.2 and 31.1 minutes for 2.0 and 4.0 mg/kg per week 
groups, respectively.17
Consistent with the findings from MOR-002, the differ-
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higher than dose differences demonstrated in MOR-004 and 
MOR-008. This finding indicated that PKs of elosulfase alfa 
are not linear over this dosing range.11,17,19 The changes over 
time were attributed to neutralizing antibodies that occur in all 
patients.14,18 The pharmacodynamic outcome was measured 
by the decrease of first morning void urine KS. The level 
of urine KS is used to determine PKs, but the level does 
not correlate with clinical response. Decreases of urine KS 
was detected in all treatment groups, consistently across the 
cohorts (MOR-002, -004, and -008).11,17,19
Preclinical data
MPS IVA mice were studied to determine the safety, efficacy, 
and tolerability of elosulfase alfa. Animals showed marked 
reduction of storage in visceral organs, bone marrow, heart 
valves, connective tissues, and ligaments after 12 weeks of 
treatment.20 Further evaluation was experimented in newborn 
MPS IVA mice receiving ERT at birth. The bone pathology 
study showed that chondrocytes were vacuolated, but the 
column structure was organized. This evidence suggested that 
the enzyme entered cartilage before the cartilage cell layer 
becomes mature bone, leading to prevention of the disorga-
nization of cartilage structure seen in MPS IV. These results 
indicated that early treatment may prevent bone pathology, 
the major symptom of MPS IV.21
Clinical trial data
Trial participants were enrolled in a multinational, mul-
ticenter, double-blind, randomized, placebo-controlled, 
24-week Phase III study (MOR-004). The cohort was divided 
into two different dose regimens (2.0 mg/kg per week and 
2.0 mg/kg QOW) infused intravenously compared to pla-
cebo. This study recruited only subjects with the ability to 
ambulate. All subjects had an average 6MWT distance ≥30 
and ≤325 m during screening. A total of 176 patients (ages 
5–57 years) were enrolled. One patient discontinued due to 
withdrawal of consent from the weekly treatment group. The 
primary efficacy measure was 6MWT, a measure of endur-
ance. Secondary efficacy outcomes were 3MSCT and urine 
KS normalization. Tertiary measures evaluated were pulmo-
nary function (FVC, MVV, and forced expiratory volume 
in 1 second). Additional tests and measures were collected, 
including anthropometric measures, audiogram to evaluate 
hearing, echocardiogram to evaluate cardiac valve function, 
corneal clouding and radiographic examination, MPS Health 
Assessment Questionnaires to evaluate quality of life, inflam-
matory markers (tumor necrosis factor α), and bone–cartilage 
metabolism (c-terminal crosslinked C-telopeptide CTX1 and 
type IIA collagen N-propeptide PIIANP).11,19
At week 24, elosulfase alfa administered weekly signifi-
cantly improved the 6MWT distance compared to placebo 
(22.5 m; P=0.0174). The 3MSCT was not significantly 
changed in both weekly and QOW cohorts compared to 
placebo. Rapid and sustained urine KS was found in both 
treatment arms. Other tertiary improvements were detected 
numerically, including FVC, MVV, standing height, and 
growth rate in subjects with expected open growth plates 
(males <18 years; females <15 years).15,19 The differences 
in audiometry, echocardiogram, corneal clouding, or lower 
extremities bone length were small. Inflammatory marker was 
not changed in treatment group. Levels of CTX1 and PIIANP 
were not increased after treatment (elevation of both mark-
ers suggests bone formation). Since the tertiary end points 
of the Phase III study were not designed to have sufficient 
power, different composite end point analysis methods such 
as prespecified composite end point and O’Brien’s rank-sum 
composite end point were applied to allow for evaluation 
of treatment impact across multiple domains. The analyses 
demonstrated that the 2.0 mg/kg per week group had received 
benefit of treatment when the combination of changes from 
baseline of 6MWT, 3MSCT, and MVV were explored.15 
The trial results recommended studies in younger and pre- 
or mildly symptomatic patients to determine the maximal 
benefit of treatment.15
The findings from ongoing high-dose 4.0 mg/kg per 
week versus recommended dose 2.0 mg/kg per week in high-
functioning subjects (≥7 years and able to walk ≥200 m in 
6MWT at screening) revealed numerical improvement in 
3MSCT, cardiopulmonary exercise test, muscle strength, 
and pain in 4.0 mg/kg per week arm.
Treatment administration
The recommended dose is 2.0 mg/kg per week intravenous 
infusion over 3.5–4.5 hours, based on infusion volume. The 
final volume is 100 mL for patients <25 kg and 250 mL for 
patients >25 kg. The ERT is diluted in 0.9% sodium chloride 
injection. For patients <25 kg, the infusion rate should be 
3 mL/h for the first 15 minutes and increased to 6 mL/h for 
the next 15 minutes. If this rate is tolerated, it can be increased 
by 6 mL/h every 15 minutes, not to exceed 36 mL/h.
For patients weighing ≥25 kg, initial infusion rate should 
be 6 mL/h for 15 minutes, and then the ramping regimen 
is begun at 12 mL/h for 15 minutes to a maximal rate of 
72 mL/h.





Premedication with nonsedative antihistamine with or 
without antipyretics should be administered 30–60 minutes 
before infusion. A nonsedating formulation is preferred due 
to the risk of sleep apnea and airway difficulty in a sedating 
antihistamine.
Adverse events and reactions
Due to the size of the cohort and the short period of time 
in use, it is likely that additional adverse reactions may be 
identified as use of this ERT continues. Of the 235 patients 
enrolled in the clinical trail, 16 (6.8%) experienced signs and 
symptoms consistent with anaphylaxis (cough, erythema, 
throat tightness, urticarial, hypotension, dyspnea, gastrointes-
tinal symptoms). The timing of these reactions was as early as 
30 minutes after beginning infusion to 3 hours after infusion 
was completed. All but two subjects were able to receive 
subsequent elosulfase alfa infusion with infusion rate adjust-
ments and/or medical intervention. Hypersensitivity reactions 
occurred in 18.7% and were observed from 30 minutes after 
start of infusion to as late as 6 days after infusions.11,12 Of 
the data from MOR-004, the most common adverse events 
were headache (20.3%), pyrexia (18.6%), vomiting (15.3%), 
nausea (13.6%), diarrhea (11.9%), fatigue (11.9%), upper 
abdominal pain, upper (8.5%), cough (8.5%), oropharyngeal 
pain (5.1%), abdominal pain (3.4%), and chills (1.7%).19
Most recently, a small study with children <5 years of 
age was completed. The group received 2.0 mg/kg per week 
for 52 weeks. Adverse events requiring infusion interruption 
and medical intervention occurred in 0.8% of infusions. 
Both growth velocity and urine KS levels were improved 
on treatment.22
Adverse reactions – prevention and 
management
Premedication with a nonsedating antihistamine with or 
without an antipyretic reduced the risk of adverse reactions 
in Phase I/II clinical trials.19 Premedication with sedating 
antihistamine, antipyretic, H
2
 blockers, leukotriene receptor 
antagonists, oral cromolyn sodium (personal communica-
tion), and/or steroids should be considered if the patient 
has a history of adverse reactions or allergies. Additionally, 
decreasing the infusion rate by 25%–50%, especially dur-
ing the first 1–2 hours, is helpful if the reaction is early in 
the infusion course (personal experience). For patients with 
airway management or positive pressure during sleep sec-
ondary to sleep apnea, an airway patency evaluation should 
be performed prior to beginning ERT. Furthermore, oxygen 
should be available during the infusion therapy.
Postponement of ERT infusion should be highly consid-
ered in patients with acute infection, fever, or respiratory 
illness, due to an increased risk of hypersensitivity reactions.13
For acute hypersensitivity reaction, immediate medical 
care should be initiated. For mild-to-moderate reactions, 
slowing or stopping infusion should be considered. Addi-
tionally, administering antihistamines, antipyretics, and/or 
steroids should be considered.
For severe anaphylaxis reactions, infusion should be dis-
continued and breathing and circulation evaluated. Stabilizing 
the airway, giving oxygen supplementation, and administer-
ing epinephrine intramuscular injection and/or intravenous 
fluids for hypotension should be considered.
Patient evaluation of elosulfase alfa
Clinical trials demonstrated that treatment improved 6MWT 
and provided positive and meaningful changes in several 
clinical parameters. Preclinical studies indicated that early and 
presymptomatic treatment could prevent some progression of 
bone pathology. Further studies are necessary to demonstrate 
the efficacy of treatment in the relatively healthy population. 
Treatment should be initiated as soon as the diagnosis is made. 
The results of treatment may be different in each patient due 
to the high heterogeneity of the natural history. Expectation 
and goals of treatment of each family are different and should 
be discussed before starting the treatment. The efficacy of 
ERT on bone is not impressive. Patients should continue to 
follow closely with orthopedics. Furthermore, growth did 
not improve with treatment; however, the age of treatment 
initiation has not been clearly elucidated. The one study in 
children <5 years of age has shown short-term growth veloc-
ity improvement; however, long-term studies have not been 
published. Various parameters should be closely monitored 
throughout the treatment course with ERT. As with any ERT 
requiring weekly infusion, the loss of quality of life due to 
the frequent infusions must be offset by the perceived benefit 
of the treatment. This logistic issue could be managed but 
requires collaboration from other supporting systems and 
persons. For example, home infusion therapy could be prefer-
ably provided during the weekends or weekday evenings for 
the adult patients to avoid their work obligation issue, while 
pediatric patients can receive treatment during the weekdays 
since arrangement can be made more easily for their educa-
tion requirement such as homework assignments or home-
schooling (especially severe mobility impaired patients). 
Patient satisfaction has been fair based on the severity of 
the symptoms existing before ERT. For severe groups, the 
expectations are improvement of pain, ADLs, and ability to 
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ambulate without using equipment. Even small changes such 
as ability to walk independently for a few feet could impact 
life (personal conversation). For mild-to-moderate symptom 
groups, the major expectations are improvement of endurance, 
exercise tolerance, and possible prevention of bone deformity 
progression. The consistency in receiving infusions was found 
to be higher in the home infusion group than those receiving 
infusions at an infusion center, due to the travel requirement.
The future of elosulfase alfa
Long-term outcome studies will be crucial to determine the 
role of elosulfase alfa on the bone outcomes of patients. Fur-
thermore, based on the natural history outcomes described, 
long-term changes in progression of disease will be crucial 
to demonstrate the long-term efficacy of ERT treatment in 
MPS IVA.7 One measurement of initiation of elosulfase alfa 
treatment will be the number of patients that remain in the 
untreated arm of the natural history study, either by choice 
or due to inaccessibility of the ERT.
Donida et al described a cohort of MPS IVA patients 
receiving ERT therapy with elevated interleukin-6 and 
decreased glutathione levels, suggesting a proinflammatory 
and pro-oxidant state in these patients.23 The study did not 
include a cohort of MPS IVA patients not receiving ERT 
for comparison. This study supports further investigation of 
using antioxidants and antiinflammatory agents in combina-
tion with ERT to optimize patient outcomes.
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